《中国图书资料分类法》分类号R735.7
The Immological Rejection Activated by Human Heptocarcinoma Transferred with Murine H-2Kb Gene
Zhang ZhixiangYuan AiliWang XiaoningZhang LiZhou Dianyuan
(The PLA Hospital in Hong Kong, Shenzhen 518048)
AbstractObjective: To strengthen the immunogenicity of hepatocarcinoma cells and activate immnological cells recognizing and killing the tumor cells. Methods: The murine MHC-Ⅰ gene H-2Kb which can express immunologial rejection antigens was transfected into human hepatocarcinoma cells HepG2 by liposome DNA mediated gene transfer. The transfection and transcription of H-2Kb gene were detected by molecular hybridization techniques. The exogeous antigens expressed on the membrane of transfected tumor cells were detected with ABC immunohistochemical method and flow cytometer. [3H] release assays were used to detect the recognizing and killing effects of lymphocytes to HepG2 cells transferred with murine H-2Kb gene. The nude mice experiment was used to further verify CTL cells killing active. Results: Southern blot hybridization showed that the H-2Kb gene was integrated into the chromosome of HepG2 cells. The RNA dot blot hybridization showed that there was transcription of H-2Kb DNA in the transfected tumor cells. ABC immunohistochemical method and flow cytometer detection showed that the murine H-2Kb antigens were expressed on the membrane of HepG2 cells. [3H] release assays showed that the cytotoxicyty to HepG2 cells transfected with H-2Kb gene was obviously higher than that to control cells. The results demonstrated that the growth of hepatocarcinoma cells which were transferred with H-2Kb gene was obviously inhibited. Conclusion: The murine MHC-Ⅰ gene H-2Kb could be transferred into the human hepatocarcinoma cells and expressed on the membrane of transferred cells. The HepG2 cells transferred with H-2Kb gene could induce human effective lymphocytes to recognize and kill these transferred tumor cells.
Key words
Key wordsH-2Kb gene; immunogenicity; hepatocarcinoma; gene transfer
肿瘤免疫原性降低是造成肿瘤细胞免疫逃逸的主要原因之一,增强肿瘤细胞的免疫原性以激活宿主免疫系统识别和杀伤相应的肿瘤细胞可能成为一种治疗肿瘤的有效手段。本实验通过基因转染方法将小鼠MHC-Ⅰ类基因H-2Kb转染人肝癌细胞株HepG2,并使此基因抗原在肝癌细胞膜上表达,从而人为地将肝癌细胞转变成带异源免疫性状的细胞,提高肝癌细胞的免疫原性,激发宿主免疫效应细胞杀伤活性。
1材料与方法
1.1脂质体介导H-2Kb基因质粒与PSV2质粒共转染肝癌细胞
HepG2细胞培养18 h,将H-2Kb基因与脂质体混合液20 μl加入培养细胞液中培养48 h(方法参照GIBCO公司产品说明书)。细胞传代后加入400 μg/mlG-418,实验同时设不加H-2Kb基因对照及单独PSV2转染对照。细胞克隆经H-2Kb斑点杂交筛选。H-2Kb基因重组表达质粒由E*Weiss教授惠赠[1]。
1.2转染细胞H-2Kb基因存在及表达情况检测
1.2.1Southern印迹杂交
制备Dig-H-2Kb DNA探针,按常规方法杂交(方法参照Mannheim公司产品说明书)。
1.2.2RNA点杂交
按常规方法进行。
1.2.3ABC免疫组化实验
操作按试剂盒(Vector公司产品)说明书进行。抗H-2Kb抗原单克隆抗体系ATCC产品。
1.2.4流式细胞仪检测
制备细胞悬液,加入抗H-2Kb抗原单克隆抗体,4℃过夜,洗涤后加入荧光标记羊抗鼠IgG抗体,37℃,40 min。
1.3H-2Kb基因转染后体外诱发效应细胞杀伤活性实验
1.3.1效应细胞制备
按常规方法进行。
1.3.2效应细胞杀伤活性检测
收获处于对数生长期的H-2Kb转染阳性、PSV2转染阳性及未转染外源基因的HepG2肝癌细胞,各加[3H]-TdR(中国原子能研究所产品)20 μCi。37℃,2 h。同时设最大释放组和自然释放组。测定CPM值,计算特异杀伤率。
1.4裸鼠实验
2~4周龄裸鼠(购自上海医科大学)随机分3组,每组10只,分别为接种H-2Kb转染HepG2肝癌细胞组、PSV2质粒转染HepG2肝癌细胞组和未转染外源基因HepG2肝癌细胞组,待肿瘤生长面积约为300 mm2后,将已制备好的人胎儿脾效应细胞每隔4 d分4次注射到3组裸鼠皮下肿瘤内,观察肿瘤生长情况。实验在第一军医大学无菌动物饲养室进行。实验数据用χ±SD表示,用SAS:软件包均数间比较,SNK法。
2结果
2.1脂质体介导H-2Kb基因表达质粒与PSV2质粒共转染HepG2肝癌细胞(图1)
H-2Kb与PSV2质粒共转染HepG2肝癌细胞后经G-418筛选,第14天出现25个细胞克隆,而未转染PSV2者在第5天细胞全部死亡。上述25个细胞克隆DNA经H-2Kb DNA点杂交筛选出4个H-2Kb阳性克隆,显示此4个克隆细胞H-2Kb基因转染成功。
图1图中显示共转染小鼠H-2Kb基因与PSV2质粒后,
用G418筛选出来的人肝癌细胞HepG2克隆
Fig. 1Human hepatocarcinoma cell clone HepG2
cotransfected with H-2Kb gene and PSV2 plasmid
was selected with G418
2.2H-2Kb基因转染后在HepG2肝癌细胞中表达
2.2.1H-2Kb基因转染后在HepG2肝癌细胞中转录
H-2Kb基因转染HepG2肝癌细胞后,筛选的4个细胞克隆RNA与Dig-H-2Kb DNA探针杂交结果阳性,显示H-2Kb基因转染成功后,能在细胞内转录成H-2Kb mRNA。
2.2.2H-2Kb基因转染后在HepG2肝癌细胞中表达
ABC免疫组化检测显示H-2Kb基因转染后HepG2肝癌细胞膜部位可见棕色显色。对照组无此现象(图2)。流式细胞仪检测显示,在相同细胞浓度下,H-2Kb基因转染组HepG2肝癌细胞显示荧光信号,对照组无此现象(图3)。上述结果说明,H-2Kb基因外显子能在HepG2肝癌细胞膜上表达H-2Kb抗原。
图2ABC免疫组化结果显示小鼠H-2Kb
